Neoplasia — MCQs

A 58-year-old woman presents with an irregular nodularity that has developed in her right breast over the past 3 months. Mammography demonstrates irregular densities in both breasts. A needle biopsy of one breast lesion shows a certain histology, and an excisional biopsy of the contralateral breast shows similar findings. Which of the following is the most likely pathologic diagnosis?

Q669Easy

The term universal tumor refers to:

Q670Medium

Cushing syndrome as a paraneoplastic syndrome is seen with all of the following malignancies EXCEPT:

Neoplasia Indian Medical PG Practice Questions and MCQs

Question 661: The Ames test is a method for detecting which of the following?

A. Carcinogenesis in rodents
B. Carcinogenesis in primates
C. Teratogenesis in any mammalian species
D. Mutagenesis in bacteria (Correct Answer)

Explanation: **Explanation:** The **Ames Test** is a rapid, high-throughput screening method used to determine the **mutagenic potential** of chemical compounds. It is based on the principle that most carcinogens are also mutagens [1]. **Why Option D is Correct:** The test utilizes a specific strain of **Salmonella typhimurium** that carries a mutation in the gene responsible for synthesizing the amino acid **histidine** (histidine auxotrophs). These bacteria cannot grow on a histidine-deficient medium. When a test chemical is added, if it is mutagenic, it induces a "back mutation" (reversion) that restores the bacteria's ability to synthesize histidine, allowing them to grow. A significant increase in colonies compared to the control indicates that the substance is a mutagen. **Why Other Options are Incorrect:** * **Options A & B:** While the Ames test is used to *screen* for potential carcinogens, it does not directly measure carcinogenesis (the formation of cancer) in rodents or primates [1]. Those require long-term, expensive *in vivo* animal bioassays. * **Option C:** Teratogenesis refers to the induction of structural defects in a fetus. The Ames test measures genetic mutations in prokaryotic cells, not developmental toxicity in mammalian embryos. **High-Yield Clinical Pearls for NEET-PG:** * **S9 Mix:** Since some chemicals only become mutagenic after being metabolized by the liver, **rat liver extract (S9 fraction)** is added to the Ames test to simulate mammalian metabolic activation. * **Correlation:** Approximately **90%** of known carcinogens test positive in the Ames test [1]. * **Other Genotoxicity Tests:** Sister Chromatid Exchange (SCE) and the Micronucleus test are used to detect chromosomal damage in mammalian cells. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 330-332.

Question 662: N-myc gene amplification is seen in which of the following tumors?

A. Burkitt's lymphoma
B. Small cell lung carcinoma
C. Neuroblastoma (Correct Answer)
D. All of the above

Explanation: ### Explanation **1. Why Neuroblastoma is the Correct Answer:** The **N-myc (MYCN)** gene is a proto-oncogene located on chromosome 2. In **Neuroblastoma**, this gene undergoes **amplification**, leading to the formation of hundreds of gene copies [1]. These are microscopically visible as **Double Minute chromosomes (dms)** or **Homogeneously Staining Regions (HSRs)**. * **Clinical Significance:** N-myc amplification is the most important prognostic factor in Neuroblastoma [1]. Its presence (found in ~25-30% of cases) indicates a **poor prognosis**, rapid tumor progression, and advanced stage, regardless of the patient's age [1]. **2. Why Other Options are Incorrect:** * **Burkitt’s Lymphoma:** This is characterized by the **translocation** of the **c-myc** gene, most commonly **t(8;14)**, involving the IgH locus [2]. It involves c-myc, not N-myc. * **Small Cell Lung Carcinoma (SCLC):** While the **L-myc** gene is frequently amplified in SCLC, N-myc is specifically the hallmark of Neuroblastoma. (Note: While some sources mention N-myc in SCLC, in the context of standard medical exams, N-myc is the classic association for Neuroblastoma). **3. NEET-PG High-Yield Clinical Pearls:** * **MYC Family Summary:** * **c-myc:** Burkitt’s Lymphoma (Translocation) [2]. * **N-myc:** Neuroblastoma (Amplification) [1]. * **L-myc:** Small Cell Lung Carcinoma (Amplification). * **Neuroblastoma Markers:** Look for increased urinary **VMA (Vanillylmandelic acid)** and **HVA (Homovanillic acid)** [1]. * **Histology:** Characterized by **Homer-Wright rosettes** (pseudorosettes). * **Staging:** N-myc status is mandatory for risk stratification according to the International Neuroblastoma Risk Group (INRG) classification [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 486-487. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 324-325.

Question 663: The RET proto-oncogene is located on which chromosome?

A. Chromosome 9
B. Chromosome 10 (Correct Answer)
C. Chromosome 11
D. Chromosome 12

Explanation: **Explanation:** The **RET (REarranged during Transfection)** proto-oncogene is located on the long arm of **Chromosome 10 (10q11.2)**. It encodes a receptor tyrosine kinase essential for the development of the neural crest-derived cells and the genitourinary system. **Why Chromosome 10 is correct:** The RET gene is a classic example of a proto-oncogene that can be activated by two distinct mechanisms: 1. **Point Mutations:** Germline mutations lead to **Multiple Endocrine Neoplasia (MEN) syndromes 2A and 2B**, as well as Familial Medullary Thyroid Carcinoma (FMTC) [1]. 2. **Gene Rearrangements:** Chromosomal translocations involving RET lead to **Papillary Thyroid Carcinoma (PTC)**, specifically the RET/PTC rearrangements [1]. **Analysis of Incorrect Options:** * **Chromosome 9:** Associated with the **ABL** proto-oncogene (involved in the t(9;22) Philadelphia chromosome in CML). * **Chromosome 11:** Home to the **WT1** (Wilms tumor) gene and the **CCND1** (Cyclin D1) gene, often involved in Mantle Cell Lymphoma via t(11;14). * **Chromosome 12:** Associated with the **KRAS** oncogene and the **MDM2** gene (often amplified in liposarcomas). **High-Yield Clinical Pearls for NEET-PG:** * **Gain-of-function** mutations in RET → MEN 2A, MEN 2B, and Medullary Thyroid Carcinoma [1]. * **Loss-of-function** mutations in RET → **Hirschsprung disease** (congenital megacolon). * **MEN 2A:** Medullary Thyroid Ca, Pheochromocytoma, Parathyroid Hyperplasia [1]. * **MEN 2B:** Medullary Thyroid Ca, Pheochromocytoma, Mucosal Neuromas, and Marfanoid habitus [1]. * Prophylactic thyroidectomy is often indicated in children carrying RET mutations to prevent aggressive Medullary Thyroid Carcinoma. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1097-1137.

Question 664: With reference to neoplasia, what does the term 'tumor progression' mean?

A. Spread of cancer to distant sites
B. Rate of growth of tumors
C. Ability of cancer cells to resemble their normal counterparts
D. Sequential appearance of features of increasing malignancy (Correct Answer)

Explanation: ### Explanation **Tumor progression** refers to the phenomenon where a tumor becomes increasingly aggressive and acquires greater malignant potential over time [1], [3]. This is not merely an increase in size, but a **sequential appearance of features of increasing malignancy**, such as faster growth rates, increased invasiveness, and the ability to metastatize [1]. The underlying molecular concept is **clonal evolution and tumor heterogeneity** [2]. Although tumors are monoclonal in origin, by the time they are clinically detectable, they are genetically heterogeneous [2]. As the tumor cells divide, they acquire new mutations [3]. Subclones that develop "fitness" advantages—such as the ability to evade the immune system or survive without growth factors—outcompete others. This Darwinian selection process leads to a more lethal cell population [2]. #### Analysis of Incorrect Options: * **Option A (Spread to distant sites):** This describes **metastasis**, which is a *result* of tumor progression but not the definition of the term itself [1]. * **Option B (Rate of growth):** This refers to the **proliferation index** (often measured by Ki-67). While growth rate increases during progression, it is only one component of the process. * **Option C (Resemblance to normal counterparts):** This describes **differentiation** [2]. A lack of resemblance is called **anaplasia**. Tumor progression usually leads to *decreased* differentiation (loss of resemblance). #### High-Yield Clinical Pearls for NEET-PG: * **Monoclonality vs. Heterogeneity:** Tumors start as **monoclonal** (one transformed cell) but become **heterogeneous** due to tumor progression [2]. * **Hallmark of Cancer:** Genomic instability is the "enabling characteristic" that allows tumor progression to occur [2], [3]. * **Clinical Significance:** Progression explains why a tumor might initially respond to chemotherapy but later recur as a drug-resistant variant [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 224-226. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 212-213. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 288-290.

Question 665: Which of the following is not considered a poor prognostic factor in neuroblastoma?

A. MYCN amplification
B. High mitosis-karyorrhexis index
C. Evidence of gangliocytic differentiation (Correct Answer)
D. Mutations of neuritogenesis genes

Explanation: **Explanation:** Neuroblastoma is the most common extracranial solid tumor of childhood [1]. Its prognosis is highly variable and depends on clinical stage, age, and specific histopathological and molecular features [1]. **Why "Evidence of gangliocytic differentiation" is the correct answer:** The Shimada classification system categorizes neuroblastomas into "favorable" and "unfavorable" histology. **Gangliocytic differentiation** (the maturation of primitive neuroblasts into mature ganglion cells [2]) indicates a shift toward a more differentiated, benign phenotype (like ganglioneuroma). Therefore, it is a **good prognostic factor**, associated with lower-grade tumors and better clinical outcomes [2]. **Analysis of Incorrect Options (Poor Prognostic Factors):** * **MYCN amplification:** This is the most important genetic predictor of poor outcome. It occurs in ~25% of cases and is associated with rapid tumor progression and resistance to therapy, regardless of stage [1]. * **High Mitosis-Karyorrhexis Index (MKI):** A high MKI (number of cells undergoing mitosis or nuclear fragmentation) indicates high cellular turnover and aggressive biological behavior, correlating with a poor prognosis. * **Mutations of neuritogenesis genes:** Recent genomic studies have identified that mutations in genes involved in neuritogenesis (like *ATRX* or *ALK*) are linked to more aggressive clinical courses, particularly in older children. **NEET-PG High-Yield Pearls:** * **Age:** Children <18 months have a better prognosis than older children [1]. * **Stage 4S:** A unique "Special" stage in infants (<1 year) that often shows spontaneous regression despite widespread dissemination (liver, skin, bone marrow). * **Biomarkers:** Elevated urinary catecholamines (VMA/HVA) are diagnostic, but **low** VMA:HVA ratios can sometimes indicate poorer prognosis [2]. * **Deletion of 1p and Gain of 17q:** Both are associated with an unfavorable prognosis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 486-487. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, p. 486.

Question 666: Neoplastic transformation in leukoplakia is seen most commonly in which of the following locations?

A. Buccal mucosa
B. Floor of mouth (Correct Answer)
C. Lateral border of tongue
D. Palate

Explanation: Leukoplakia is a clinical term for a white patch or plaque that cannot be characterized clinically or pathologically as any other disease [1]. While the **buccal mucosa** is the most frequent site for the occurrence of leukoplakia, the risk of malignant transformation varies significantly by anatomical site. **1. Why "Floor of the Mouth" is correct:** The floor of the mouth and the ventral surface of the tongue are considered "high-risk" zones. Although leukoplakia occurs less frequently here than on the cheeks, these areas show the highest rates of dysplasia and progression to squamous cell carcinoma (SCC). This is likely due to the pooling of saliva containing carcinogens (like tobacco and alcohol) in the dependent areas of the oral cavity and the relatively thin, non-keratinized nature of the epithelium in these regions. **2. Analysis of Incorrect Options:** * **Buccal Mucosa:** This is the **most common site** for the clinical presentation of leukoplakia, but it has a relatively low rate of malignant transformation compared to the floor of the mouth. * **Lateral Border of Tongue:** This is the second most common site for malignant transformation. While high-risk, statistically, the floor of the mouth carries a slightly higher transformation potential in most classic pathological series. * **Palate:** Leukoplakia on the hard palate is often associated with "Nicotine Stomatitis" (reverse smoking), but generalized palatal leukoplakia has a lower transformation rate than the floor of the mouth. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site of Leukoplakia:** Buccal mucosa. * **Highest risk of Malignancy:** Floor of the mouth > Tongue (Lateral/Ventral) > Lower lip. * **Erythroplakia:** A red, velvety patch that has a much higher risk of malignancy (approx. 50-90%) than leukoplakia. * **Speckled Leukoplakia (Erythroleukoplakia):** Carries a higher risk of transformation than homogenous leukoplakia. * **Histology:** The presence of **epithelial dysplasia** is the most important prognostic indicator for malignant transformation [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Alimentary System Disease, pp. 344-345.

Question 667: Which of the following is a risk factor for bladder carcinoma?

A. Clonorchis sinensis
B. Schistosoma hematobium (Correct Answer)
C. Plasmodium
D. None of the above

Explanation: **Explanation:** The correct answer is **Schistosoma haematobium**. This parasite is a well-established risk factor for bladder cancer, specifically **Squamous Cell Carcinoma (SCC)**. **1. Why Schistosoma haematobium is correct:** * **Mechanism:** This trematode (blood fluke) inhabits the vesical venous plexuses. Its eggs are deposited in the bladder wall, leading to chronic inflammation, irritation, and the formation of granulomas. * **Malignancy:** Persistent chronic inflammation induces squamous metaplasia of the transitional epithelium (urothelium). Over time, this progresses to dysplasia and ultimately Squamous Cell Carcinoma [2]. While Transitional Cell Carcinoma (TCC) is the most common bladder cancer worldwide, in endemic areas for Schistosomiasis (like Egypt), SCC is more prevalent [2]. **2. Why other options are incorrect:** * **Clonorchis sinensis:** Also known as the Chinese Liver Fluke, this parasite inhabits the bile ducts. It is a major risk factor for **Cholangiocarcinoma** (bile duct cancer), not bladder cancer. * **Plasmodium:** This is the causative agent of Malaria. While it causes significant systemic morbidity and hemolysis, it has no known association with oncogenesis in the urinary tract. **High-Yield Clinical Pearls for NEET-PG:** * **Most common bladder cancer (Global):** Transitional Cell Carcinoma (TCC) [2]. * **Most common bladder cancer (Schistosomiasis endemic areas):** Squamous Cell Carcinoma (SCC) [1]. * **Other Risk Factors for Bladder Cancer:** Smoking (most common overall), Occupational exposure to Aniline dyes (2-Naphthylamine), and long-term Cyclophosphamide use [2]. * **Classic Presentation:** Painless gross hematuria in an older male [3]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 972-973. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 968-970. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 971-972.

Question 668: A 58-year-old woman presents with an irregular nodularity that has developed in her right breast over the past 3 months. Mammography demonstrates irregular densities in both breasts. A needle biopsy of one breast lesion shows a certain histology, and an excisional biopsy of the contralateral breast shows similar findings. Which of the following is the most likely pathologic diagnosis?

A. Colloid carcinoma
B. Lobular carcinoma in situ (Correct Answer)
C. Malignant phyllodes tumor
D. Medullary carcinoma

Explanation: **Explanation:** The key to this question lies in the clinical presentation of **bilaterality** and **multicentricity**. **Why Lobular Carcinoma In Situ (LCIS) is correct:** LCIS is characterized by a proliferation of small, discohesive cells (due to loss of **E-cadherin**) filling the acini of the lobules. Unlike ductal carcinomas, LCIS is frequently **bilateral (up to 30-40% of cases)** and multicentric [1]. It is often an incidental finding because it typically does not form a distinct clinical mass or produce characteristic mammographic calcifications. In this scenario, the presence of similar lesions in both breasts strongly points toward LCIS as the most likely diagnosis. **Why the other options are incorrect:** * **Colloid (Mucinous) Carcinoma:** Usually presents as a slow-growing, circumscribed, soft/gelatinous mass in older women. It is typically unilateral. * **Malignant Phyllodes Tumor:** These are large, rapidly growing stromal tumors. While they can be aggressive, they are almost always unilateral and present as a palpable "leaf-like" mass. * **Medullary Carcinoma:** Characterized by large pleomorphic cells with a lymphoid stroma (often associated with BRCA1). It typically presents as a well-circumscribed unilateral mass. **High-Yield Clinical Pearls for NEET-PG:** * **LCIS Marker:** Loss of **E-cadherin** expression (due to CDH1 gene mutation) is the hallmark, leading to the discohesive cell pattern. * **Risk Factor:** LCIS is considered a **risk factor** (indicator) for developing invasive carcinoma in *either* breast, not necessarily a direct precursor. * **Bilateral Breast Cancer:** Whenever a question mentions bilateral or multicentric breast lesions, **Lobular** (either LCIS or Invasive Lobular Carcinoma) should be your top differential [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 454-455.

Question 669: The term universal tumor refers to:

A. Adenoma
B. Papilloma
C. Fibroma
D. Lipoma (Correct Answer)

Explanation: ### Explanation The correct answer is **Lipoma (Option D)**. **Why Lipoma is the "Universal Tumor":** A lipoma is a benign tumor composed of mature adipocytes (fat cells) [1]. It is referred to as the **"universal tumor"** or the **"ubiquitous tumor"** because fat is distributed throughout the entire body. Consequently, a lipoma can arise in almost any anatomical location—subcutaneous tissue, internal organs (like the gut or heart), and even within muscles or bones. It is the most common mesenchymal tumor in adults [1]. **Analysis of Incorrect Options:** * **A. Adenoma:** This is a benign epithelial tumor of glandular origin. While common in specific organs (like the thyroid, colon, or pituitary), it is restricted to glandular tissues and is not "universal." * **B. Papilloma:** This is a benign epithelial tumor growing exophytically (outward) in finger-like fronds. It is specific to surface epithelium (skin or mucous membranes) and does not occur in non-epithelial sites. * **C. Fibroma:** This is a benign tumor of fibrous connective tissue [1]. While widespread, it is clinically less common than lipomas and does not carry the "universal" moniker in standard pathological nomenclature. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Subcutaneous tissue of the trunk, neck, and proximal extremities [1]. * **Clinical sign:** Usually presents as a soft, mobile, painless mass (often called a "slippery tumor"). * **Cytogenetics:** Often associated with rearrangements of chromosome **12q13-15** (HMGA2 gene). * **Angiolipoma:** A variant of lipoma that is characteristically **painful** and contains prominent vascularity. * **Microscopy:** Composed of lobules of mature white adipocytes separated by thin fibrous septa; they are indistinguishable from normal fat except for the presence of a delicate capsule [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Bones, Joints, and Soft Tissue Tumors, p. 1222.

Question 670: Cushing syndrome as a paraneoplastic syndrome is seen with all of the following malignancies EXCEPT:

A. Bronchial carcinoid
B. Thymus carcinoid
C. Medullary carcinoma thyroid
D. Papillary carcinoma thyroid (Correct Answer)

Explanation: **Explanation:** The core concept behind this question is the **ectopic production of ACTH** (Adrenocorticotropic Hormone) by non-pituitary tumors, which leads to **Cushing Syndrome**. This is a classic example of a paraneoplastic syndrome. **Why Papillary Carcinoma Thyroid (Option D) is the correct answer:** Papillary carcinoma of the thyroid is a well-differentiated tumor derived from follicular cells. It typically presents as a cold nodule and spreads via lymphatics. It is **not** associated with neuroendocrine differentiation or the secretion of ectopic hormones like ACTH. Therefore, it does not cause Cushing syndrome. **Analysis of Incorrect Options:** * **Bronchial Carcinoid & Thymus Carcinoid (Options A & B):** Carcinoid tumors are neuroendocrine tumors (NETs). They possess neurosecretory granules and have the biochemical machinery to synthesize and secrete peptide hormones, most commonly ACTH. Bronchial carcinoids are among the most frequent causes of ectopic ACTH syndrome. * **Medullary Carcinoma Thyroid (Option C):** Unlike papillary carcinoma, Medullary Thyroid Carcinoma (MTC) arises from **Parafollicular C-cells**, which are neuroendocrine in origin [2]. MTC is known to secrete calcitonin, but it can also ectopically produce ACTH, CRH, or serotonin [1]. **High-Yield NEET-PG Pearls:** 1. **Small Cell Carcinoma of the Lung** is the *most common* cause of ectopic ACTH-mediated Cushing syndrome. 2. **Neuroendocrine tumors (NETs)** are the primary culprits for paraneoplastic Cushing (Lung, Thymus, Pancreas, and Medullary Thyroid) [1]. 3. **Distinction:** Cushing *Disease* refers specifically to a pituitary adenoma secreting ACTH, whereas Cushing *Syndrome* is the clinical state of cortisol excess from any cause (including ectopic sources). 4. Ectopic ACTH production often presents with rapid onset, severe hypokalemia, and hyperpigmentation (due to MSH-like activity of ACTH precursors). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1102-1103. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 430-431.

Practice by Chapter

Nomenclature and Classification of Tumors

Practice Questions

Characteristics of Benign and Malignant Neoplasms

Practice Questions

Molecular Basis of Cancer

Practice Questions

Carcinogenesis and Carcinogens

Practice Questions

Tumor Progression and Metastasis

Practice Questions

Tumor Markers

Practice Questions

Paraneoplastic Syndromes

Practice Questions

Genetic Basis of Cancer

Practice Questions

Tumor Immunity

Practice Questions

Cancer Epidemiology and Prevention

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Neoplasia — MCQs

Neoplasia — MCQs

On this page

Practice by Chapter

Want unlimited practice?